Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on July 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results released for quarter ended June 30, 2026.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results released for quarter ended June 30, 2026
- Detailed results and management commentary available in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $183.6M, up 16% year over year, with global active patients up 18% to 5,128
- Adjusted EBITDA $10.8M versus $(9.9)M, supporting management’s path toward profitability
- Net loss narrowed to $15.7M, or $0.13 per share, from $40.1M, or $0.36, in Q2 2025
- Optune Pax CE Mark expands European launch opportunity, with Germany first market and 285 U.S. patients
- 2026 guidance raised: revenue $710M-$725M and Adjusted EBITDA $0M-$15M, versus prior ranges of $690M-$710M and $(15)M-$0ીએમ
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.